Download PDF
Thromb Haemost 1993; 70(05): 730-735
DOI: 10.1055/s-0038-1649660
Clinical Studies
Schattauer GmbH Stuttgart

Heparin Cofactor II Deficiency in Patients Infected with the Human Immunodeficiency Virus

P Toulon
1   Laboratoire d’Hématologie, Hôpital Cochin, Paris, France
,
M Lamine
1   Laboratoire d’Hématologie, Hôpital Cochin, Paris, France
,
I Ledjev
1   Laboratoire d’Hématologie, Hôpital Cochin, Paris, France
,
T Guez
2   Département de Médecine Interne, Hôpital Cochin, Paris, France
,
M E Holleman
1   Laboratoire d’Hématologie, Hôpital Cochin, Paris, France
,
D Sereni
2   Département de Médecine Interne, Hôpital Cochin, Paris, France
,
D Sicard
2   Département de Médecine Interne, Hôpital Cochin, Paris, France
› Author Affiliations
Further Information

Publication History

Received 13 April 1992

Accepted after revision 28 June 1993

Publication Date:
05 July 2018 (online)

  PDF Download  Permissions and Reprints

Summary

In human plasma, heparin cofactor II (HCII) is a thrombin inhibitor, whose deficiency has been reported to be associated with recurrent thrombosis. The finding of two cases of low plasma HCII activity in two patients infected with the human immunodeficiency virus (HIV) led us to investigate this coagulation inhibitor in the plasma of a larger population of HIV-infected patients. The mean plasma HCII activity was significantly lower in 96 HIV-infected patients than in 96 age- and sex-matched healthy individuals (0.75 ± 0.24 vs 0.99 ± 0.17 U/ml, p <0.0001). HCII antigen concentration was decreased to the same extent as the activity. The proportion of subjects with HCII deficiency was significantly higher in the HIV-infected group than in healthy individuals (38.5% vs 2.1%). In addition, HCII was significantly lower in AIDS patients than in other HIV-infected patients, classified according to the Centers for Disease Control (CDC) on the basis of an absolute number of circulating CD4+ lymphocytes below 200 x 106/1. The link between HCII and immunodeficiency is further suggested by significant correlations between HCII activity and both the absolute number of CD4+ lymphocytes and the CD4+ to CD8+ lymphocyte ratio. Nevertheless, the mean HCII level was not different in the various groups of patients classified according to clinical criteria, except in CDC IVD patients in whom HCII levels were significantly lower. In addition, no correlation could be demonstrated between HCII and protein S activities, another coagulation inhibitor whose plasma level was also found to be decreased in HIV-infected patients. A similar prevalence of HCII deficiency was also found in a small series of 7 HIV-infected patients who developed thrombotic episodes, an unusual complication of the infection. This suggests that, in HIV-infected patients, HCII deficiency is not in itself the causative factor for the development of thrombosis.

 

  • References

  • 1 Tollefsen DM, Blank MK. Detection of a new heparin-dependent inhibitor of thrombin in human plasma. J Clin Invest 1981; 68: 589-596
    CrossrefPubMedGoogle Scholar
  • 2 Griffith MJ, Noyes CM, Church FC. Reactive site peptide structural similarity between heparin cofactor II and antithrombin III. J Biol Chem 1985; 260: 2218-2225
    PubMedGoogle Scholar
  • 3 Blinder MA, Marasa JC, Reynolds CH, Deaven LL, Tollefsen DM. cDNA sequence, chromosome localization, restriction fragment length polymorphism and expression of heparin cofactor II in Escherichia coli. Biochemistry 1988; 27: 752-759
    CrossrefPubMedGoogle Scholar
  • 4 Carrell RW, Christey PB, Boswell DR. Serpins: Antithrombin and other inhibitors of coagulation and fibrinolysis. Evidence from amino acid sequence. In: Thrombosis and Haemostasis. Verstraete M, Vermylen J, Lijnen R, Arnout J. (eds). Leuven University Press; Leuven: 1987. pp 1-15
    Google Scholar
  • 5 Rosenberg RD, Damus PS. The purification and mechanism of action of human antithrombin-heparin cofactor. J Biol Chem 1973; 24S: 6490-6505
    PubMedGoogle Scholar
  • 6 Parker KA, Tollefsen DM. The protease specificity of heparin cofactor II. Inhibition of thrombin generated during coagulation. J Biol Chem 1985; 260: 3501-3505
    PubMedGoogle Scholar
  • 7 Rosenberg RD. Actions and interactions of antithrombin and heparin. New Engl J Med 1975; 292: 146-150
    CrossrefPubMedGoogle Scholar
  • 8 Tollefsen DM, Majerus DW, Blank MK. Heparin cofactor II. Purification and properties of a heparin-dependent inhibitor of thrombin. J Biol Chem 1982; 257: 2162-2169
    PubMedGoogle Scholar
  • 9 Tollefsen DM, Pestka CA, Monafo WJ. Activation of heparin cofactor II by dermatan sulfate. J Biol Chem 1983; 258: 6713-3716
    PubMedGoogle Scholar
  • 10 Egeberg O. Inherited antithrombin deficiency causing thrombophilia. Thromb Diathes Haemorrh 1965; 13: 516-530
    PubMedGoogle Scholar
  • 11 Tran TH, Marbet GA, Duckert F. Assocation of hereditary heparin cofactor II deficiency with thrombosis. Lancet 1985; II: 413-414
    PubMedGoogle Scholar
  • 12 Sie P, Dupouy D, Pichon J, Boneu B. Constitutional heparin cofactor II deficiency associated with recurrent thrombosis. Lancet 1985; II: 414-416
    PubMedGoogle Scholar
  • 13 Bertina RM, van derLinden IK, Engeser L, Muller HP, Brommer EJP. Hereditary heparin cofactor II deficiency and the risk of development of thrombosis. Thromb Haemostas 1987; 57: 196-200
    PubMedGoogle Scholar
  • 14 Toulon PA, Vitoux JF, Fiessinger JN, Sultan Y, Aiach M. Heparin cofactor II deficiency: a risk factor for thrombosis?. Circulation 1988; 78 (suppl. II): 326
    PubMedGoogle Scholar
  • 15 Mannucci PM, Tripodi A. Laboratory screening of inherited thrombotic syndromes. Thromb Haemostas 1987; 57: 247-251
    PubMedGoogle Scholar
  • 16 Cohen JR, Lackner R, Wenig P, Pillari G. Deep venous thrombosis in patients with AIDS. NY State J Med 1990; 90: 159-161
    PubMedGoogle Scholar
  • 17 Tollefsen DM, Pestka CA. Heparin cofactor II activity in patients with disseminated intravascular coagulation and hepatic failure. Blood 1985; 66: 769-774
    PubMedGoogle Scholar
  • 18 Massouh M, Jatoi A, Gordon EM, Ratnoff OD. Heparin cofactor II activity in plasma during pregnancy and oral contraceptive use. J Lab Clin Med 1989; 114: 697-699
    PubMedGoogle Scholar
  • 19 Toulon P, Bardin JM, Blumenfeld N. Increased heparin cofactor II levels in women taking oral contraceptives. Thromb Haemostas 1990; 64: 365-368
    PubMedGoogle Scholar
  • 20 Centers for Disease Control. Revised classification system for HIV’ infection and expanded AIDS surveillance case definition for adolescents and adults. 1992
    PubMedGoogle Scholar
  • 21 Centers for Disease Control, US Department of Health and Human Services. Revision of the case definition of acquired immunodeficiency syndrome for national reporting, United States. MMWR 1985; 34: 372-375
    PubMedGoogle Scholar
  • 22 Laurell CB. Quantitative estimation of proteins by electrophoresis in agarose gel-containing antibodies. Anal Biochem 1966; 15: 45-52
    CrossrefPubMedGoogle Scholar
  • 23 Toulon P, Chadeuf G, Aiach M. Purification of Heparin cofactor II from human plasma. J Chromatogr 1991; 539: 493-500
    CrossrefPubMedGoogle Scholar
  • 24 Wolf M, Boyer-Neumann C, Martinolli JL, Leroy-Matheron C, Amiral J, Meyer D, Larrieu MJ. A new functional assay for human proteins S activity using activated factor V as substrate. Thromb Haemostas 1989; 64: 1144-1145
    PubMedGoogle Scholar
  • 25 Comp OC, Doray D, Patton D, Esmon CT. An abnormal plasma distribution of protein S occurs in functional protein S deficiency. Blood 1986; 67: 504-508
    PubMedGoogle Scholar
  • 26 Dupouy D, Sié P, Dol F, Boneu B. A simple method to measure dermatan sulfate at sub-microgram concentration in plasma. Thromb Haemostas 1988; 60: 236-239
    PubMedGoogle Scholar
  • 27 von ClaussA. Gerinnungsphysiologische Schnell-Methode zur Be-stimmung des Fibrinogens. Acta Haematol 1957; 17: 237-246
    CrossrefPubMedGoogle Scholar
  • 28 Giorgi JV, Nishanian PG, Schmid I, Hultin LE, Cheng HL, Detels R. Selective alterations in immunoregulatory lymphocytes subsets in early HIV (human T-lymphotropic virus type III/lymphadenopathy associated virus infection). J Clin Immunol 1987; 7: 140-150
    CrossrefPubMedGoogle Scholar
  • 29 Bloom EJ, Abrams DI, Rodgers G. Lupus anticoagulant in the acquired immunodeficiency syndrome. JAMA 1986; 256: 491-493
    CrossrefPubMedGoogle Scholar
  • 30 Cohen AJ, Philips TM, Kessler CM. Circulating coagulation inhibitors in the acquired immunodeficiency syndrome. Ann Intern Med 1986; 104: 175-180
    CrossrefPubMedGoogle Scholar
  • 31 Gold JE, Haubenstock A, Zalusky R. Lupus anticoagulant and AIDS. N Engl J Med 1986; 314: 1252
    PubMedGoogle Scholar
  • 32 Lafeuillade A, Alessi MC, Poizot-Martin I, Dhiver C, Quilichini R, Aubert L, Gastaut A, Juhan-Vague I. Protein S deficiency and HIV infection. N Engl J Med 1991; 324: 1220
    PubMedGoogle Scholar
  • 33 Schved JF, Gris JC, Michaud A, Amiral J, Quincat D, Arnaud A, Martinez P. Study of the protein S system in HIV-infected patients: acquired protein S deficiency or unsuitable assays?. Blood Coag Fibrinol 1992; 3: 295-301
    CrossrefPubMedGoogle Scholar
  • 34 Lafeuillade A, Alesi MC, Poizot-Martin I, Boyer-Neumann C, Zandotti C, Quilichini R, Aubert L, Tamalet C, Juhan-Vague I, Gastaut JA. Endothelial cell dysfunction in HIV infection. J Acquir Immune Defic Syndr 1992; 5: 127-131
    PubMedGoogle Scholar
  • 35 Bissuel F, Berruyer M, Causse X, Dechavanne M, Trepo C. Acquired protein S deficiency: correlation with advanced disease in HIV-1-infected patients. J Acquir Immune Defic Syndr 1992; 5: 484-489
    PubMedGoogle Scholar
  • 36 Re MC, Furlini G, Cenacchi G, Preda P, La PlacaM. Human immunodeficiency virus type 1 infection of endothelial cells in vitro. Microbiologia 1991; 14: 149-152
    PubMedGoogle Scholar
  • 37 Steffan AM, Lafon ME, Gendrault JL, Schweitzer C, Royer C, Jaeck D, Arnaud JP, Schmitt MP, Aubertin AM, Kirn A. Primary cultures of endothelial cells from the human liver sinusoid are permissive for human immunodeficiency virus type 1. Proc Natl Acad Sci USA 1992; 89: 1582-1586
    CrossrefPubMedGoogle Scholar
  • 38 Drouet L, Scrobohaci ML, Janier M, Baudin B. Endothelial cells: target for the HIV1 virus?. Nouv Rev Fr Hematol 1990; 32: 103-106
    PubMedGoogle Scholar
  • 39 Beilke MA. Vascular endothelium in immunology and infectious disease. Rev Infect Dis 1989; 11: 273-283
    CrossrefPubMedGoogle Scholar
  • 40 Teiltel JM, Shore A, Read SE, Schiavone A. Immune function of vascular endothelial cells is impaired by HIV. J Infect Dis 1989; 160: 551-552
    CrossrefPubMedGoogle Scholar
  • 41 Janier M, Flageul B, Drouet L, Scrobohaci ML, Villette JM, Palangie A, Cottenot F. Cutaneous and plasma values of von Willebrand factor in AIDS: a marker of endothelial stimulation?. J Invest Dermatol 1988; 90: 703-707
    CrossrefPubMedGoogle Scholar
  • 42 Boneu B, Abbal M, Plante J, Bierme R. Factor VIII complex and endothelium damage. Lancet 1975; I: 1430
    PubMedGoogle Scholar
  • 43 McGuire EA, Tollefsen DM. Activation of heparin cofactor II by fibroblasts and smooth muscle cells. J Biol Chem 1987; 262: 169-175
    PubMedGoogle Scholar
  • 44 De ProstD, Katlama C, Pialoux G, Karsenty-Mathonnet F, Wolff M. Heparin-like anticoagulant associated with AIDS. Thromb Haemostas 1987; 57: 239
    PubMedGoogle Scholar
  • 45 Toulon P, Moulonget-Doleris L, Costa JM, Aiach M. Heparin cofactor II deficiency in renal allograft recipients: no correlation with the development of thrombosis. Thromb Haemostas 1991; 65: 20-24
    PubMedGoogle Scholar
  • 46 Toulon P, Ledjev I, Ozier Y, Gamier JF, Houssin D. Lack of correction of acquired heparin cofactor II deficiency in patients with liver failure after successful liver transplantation. Thromb Haemostas 1992; 68: 230-231
    PubMedGoogle Scholar
  • 47 Sandset PM, Andersson TR. Coagulation inhibitor levels in pneumonia and stroke: changes due to consumption and acute phase reaction. J Intern Med 1989; 225: 311-316
    CrossrefPubMedGoogle Scholar
  • 48 Toulon P, Vitoux JF, Fiessinger JN, Sicard D, Aiach M. Heparin cofactor II: an acute phase reactant in patients with deep vein thrombosis. Blood Coag Fibrinol 1991; 2: 435-439
    CrossrefPubMedGoogle Scholar
  • 49 Feinstein DL. Lupus anticoagulant, thrombosis and fetal loss. N Engl J Med 1985; 313: 1348-1350
    CrossrefPubMedGoogle Scholar
  • 50 Rosenberg RD, Bauer KA. Thrombosis in inherited deficiencies of antithrombin III, protein C and protein S. Hum Pathol 1987; 18: 253-262
    CrossrefPubMedGoogle Scholar
  • 51 Joshi W, Pawel B, Connor E, Sharer L, Oleske JM, Morrison S, Marin-Garcia J. Arteriopathy in children with acquired immune deficiency syndrome. Pediatr Pathol 1987; 7: 261-265
    PubMedGoogle Scholar
  • 52 Meyohas MC, Roullet E, Rozioux C, Aymard A, Pelosse B, Eliasceiwicz M, Frottier J. Cerebral venous thrombosis and dual primary infection with human immunodeficiency virus and cytomegalovirus. J Neurol Neurosurg Psychiatry 1989; 52: 1010-1011
    CrossrefPubMedGoogle Scholar
  • 53 Lewis B, Brosgart C, Bresnik M, Jacobson S. Venous thromboembolic disease in AIDS. Abstract FB 506. Proceedings of the VIth International Conference on AIDS San Francisco: 06/1990
    Google Scholar
  • 54 Pulik M, Lefebvre d’Hellancourt S, Couderc LJ, Matheron S, Saimot A, Mahe A. Unexplained venous thrombosis in HIV infected patients. Abstract 2038. Proceedings of the Vlth International Conference on AIDS San Francisco: 06/1990
    Google Scholar